Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Assets (2016 - 2025)

Fate Therapeutics' Current Assets history spans 14 years, with the latest figure at $208.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 28.5% year-over-year to $208.7 million; the TTM value through Dec 2025 reached $208.7 million, down 28.5%, while the annual FY2025 figure was $208.7 million, 28.5% down from the prior year.
  • Current Assets reached $208.7 million in Q4 2025 per FATE's latest filing, down from $221.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $804.3 million in Q1 2021 to a low of $208.7 million in Q4 2025.
  • Average Current Assets over 5 years is $441.5 million, with a median of $393.3 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 286.23% in 2021, then plummeted 37.06% in 2025.
  • A 5-year view of Current Assets shows it stood at $633.4 million in 2021, then decreased by 20.74% to $502.1 million in 2022, then tumbled by 33.97% to $331.5 million in 2023, then decreased by 11.95% to $291.9 million in 2024, then fell by 28.5% to $208.7 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Current Assets are $208.7 million (Q4 2025), $221.3 million (Q3 2025), and $230.4 million (Q2 2025).